About the Company
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FREQ News
Frequency Therapeutics (NASDAQ: FREQ)
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person’s innate regenerative potential to restore ...
Frequency Therapeutics Inc.
Huang's Nvidia, one of the top performing stocks over the last year, will issue what's expected to be a whopper of an earnings report on Wednesday. The standard deduction reduces the amount of ...
Korro Bio absorbs Frequency Therapeutics in reverse biotech merger
Venture-backed Korro Bio of Cambridge said Friday it will absorb financially struggling Frequency Therapeutics through a reverse merger in which Korro will take over Frequency’s public stock ...
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
2022 Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced ...
Korro Bio Inc (KRRO)
Tuesday - Korro Bio Inc. (NASDAQ:KRRO ... The biotechnology company, known for its... Investing.com - Frequency Thera (NASDAQ: FREQ) reported second quarter EPS of $-0.300, $0.06 better than ...
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology ... reductions in arrhythmia frequency and severity, and prevention of adverse fibrotic ...
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel ...
Q4 2023 Seres Therapeutics Inc Earnings Call
Rob Windsor; Head of Investor Relations and Corporate Communications; Seres Therapeutics Inc Eric Shaff; President, Chief Executive Officer, Director; Seres Therapeutics Inc Teresa Young; Executive ...
Korro Bio Inc (KRRO)
Investing.com - Frequency Thera (NASDAQ: FREQ) reported second quarter EPS of $-0.300, $0.06 better than the analyst estimate of $-0.360. Revenue for the quarter came in at $0 ...
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rh ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 11, 2024 CytomX Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge ...
Loading the latest forecasts...